Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · see citing works

p53 Mutations in Human Cancers

Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

p21 is a universal inhibitor of cyclin kinases

Xiong, Y., Hannon, G., Zhang, H., Casso, D., Kobayashi, R., & Beach, D. (1993) · Nature · doi:10.1038/366701a0 · Cited by 3,691 · see citing works

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,177 · see citing works

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works

Requirement for p53 and p21 to Sustain G ₂ Arrest After DNA Damage

Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · see citing works

The p53 pathway: positive and negative feedback loops

Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967 · see citing works

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · see citing works

Decision making by p53: life, death and cancer

Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,063 · see citing works

The MDM2 gene amplification database

Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982 · see citing works

p53 and Human Cancer: The First Ten Thousand Mutations

Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 980 · see citing works

Inhibiting the p53–MDM2 interaction: an important target for cancer therapy

Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765 · see citing works

The p53–Mdm2 module and the ubiquitin system

Michael, D., & Oren, M. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 759 · see citing works

NPAT links cyclin E–Cdk2 to the regulation of replication-dependent histone gene transcriptionPreprint

Zhao, J., Kennedy, B. K., Lawrence, B. D., Barbie, D. A., Matera, A. G., Fletcher, J. A., & Harlow, E. (2000) · Genes & Development · doi:10.1101/gad.827700 · Cited by 665 · see citing works

MDM2 — master regulator of the p53 tumor suppressor protein

Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641 · see citing works

Analysis of p53-regulated gene expression patterns using oligonucleotide arraysPreprint

Zhao, R., Gish, K., Murphy, M. E., Yin, Y., Notterman, D. A., Hoffman, W. H., Tom, E., Mack, D. H., & Levine, A. J. (2000) · Genes & Development · doi:10.1101/gad.14.8.981 · Cited by 631 · see citing works

Functions of the MDM2 oncoprotein

Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050273 · Cited by 573 · see citing works

Regulation of p53 stability

Ashcroft, M. A., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1203012 · Cited by 407 · see citing works

DNA microarrays identification of primary and secondary target genes regulated by p53

Kannan, K., Amariglio, N., Rechavi, G., Jacob‐Hirsch, J., Kela, I., Kaminski, N., Getz, G. A., Domany, E., & Givol, D. (2001) · Oncogene · doi:10.1038/sj.onc.1204319 · Cited by 331 · see citing works

MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting

Bond, G. L., Hu, W., & Levine, A. J. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 310 · see citing works

P53 and Prognosis

Vousden, K. H., & Prives, C. L. (2005) · Cell · doi:10.1016/j.cell.2004.12.027 · Cited by 259 · see citing works

Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis

Thompson, T., Tovar, C., Yang, H. S., Carvajal, D. M., Vu, B. T., Xu, Q., Wahl, G. M., Heimbrook, D. C., & Vassilev, L. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410233200 · Cited by 232 · see citing works

Retinoids: present role and future potential

Evans, T. R. J., & Kaye, S. B. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690312 · Cited by 218 · see citing works

What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?

Picksley, S. M., & Lane, D. P. (1993) · BioEssays · doi:10.1002/bies.950151008 · Cited by 207 · see citing works

Transcription, apoptosis and p53: catch-22

Schüler, M., & Green, D. R. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.01.001 · Cited by 161 · see citing works

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.

Yang, H. S., Filipovic, Z., Brown, D. A., Breit, S. N., & Vassilev, L. T. (2003) · PubMed · Cited by 157 · see citing works

DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1

Kannan, K., Kaminski, N., Rechavi, G., Jacob‐Hirsch, J., Amariglio, N., & Givol, D. (2001) · Oncogene · doi:10.1038/sj.onc.1204446 · Cited by 156 · see citing works

Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells.

Satyamoorthy, K., Chehab, N. H., Waterman, M. J. F., Lien, M. C., El‐Deiry, W. S., Herlyn, M., & Halazonetis, T. D. (2000) · PubMed · Cited by 98 · see citing works

Role of Apoptosis and Apoptosis-Related Genes in Cellular Response and Antitumor Efficacy of Anthracyclines

Perego, P., Corna, E., Cesare, M. D., Gatti, L., Polizzi, D., Pratesi, G., Supino, R., & Zunino, F. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373994 · Cited by 91 · see citing works

Flow Cytometric Methods for Detection and Quantifi cation of Apoptosis

Steensma, D. P., Timm, M., & Witzig, T. E. (2003) · Humana Press eBooks · doi:10.1385/1-59259-380-1:323 · Cited by 43 · see citing works

Exploiting the p53 pathway for cancer diagnosis and therapy.

Lane, D. P. (1999) · PubMed · Cited by 34 · see citing works

Untitled work

Berner (1996) · doi:10.1002/(sici)1098-2264(199612)17:4

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak‐Jones, C. L., Wolff, D. J., Younes, A., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,054 · see citing works

Modes of p53 regulation.

Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610 · see citing works

Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis

Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N. B.-C., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works

The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression

Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · see citing works

Awakening guardian angels: drugging the p53 pathway

Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · see citing works

Acetylation Is Indispensable for p53 Activation

Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838 · see citing works

In Vitro Expansion of Human Gastric Epithelial Stem Cells and Their Responses to Bacterial Infection

Bartfeld, S., Bayram, T., van de Wetering, M., Huch, M., Begthel, H., Kujala, P., Vries, R., Peters, P. J., & Clevers, H. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.09.042 · Cited by 820 · see citing works

p53 Dynamics Control Cell Fate

Purvis, J. E., Karhohs, K. W., Mock, C., Batchelor, E., Loewer, A., & Lahav, G. (2012) · Science · doi:10.1126/science.1218351 · Cited by 770 · see citing works

Encoding and Decoding Cellular Information through Signaling Dynamics

Purvis, J. E., & Lahav, G. (2013) · Cell · doi:10.1016/j.cell.2013.02.005 · Cited by 805 · see citing works

Inhibiting NF-κB activation by small molecules as a therapeutic strategy

Gupta, S. C., Sundaram, C., Reuter, S., & Aggarwal, B. B. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.004 · Cited by 762 · see citing works

Drugging the p53 pathway: understanding the route to clinical efficacy

Khoo, K. H., Verma, C. S., & Lane, D. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4236 · Cited by 723 · see citing works

The genetics of the p53 pathway, apoptosis and cancer therapy

Vázquez, A., Bond, E. E., Levine, A. J., & Bond, G. L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2656 · Cited by 674 · see citing works

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

Chang, Y. S., Graves, B. J., Guerlavais, V., Tovar, C., Packman, K. E., To, K.-H., Olson, K. A., Kesavan, K. P., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 666 · see citing works

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 657 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works

The role of p53 in cancer drug resistance and targeted chemotherapy

Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2016) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 590 · see citing works

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

PROTACs: An Emerging Therapeutic Modality in Precision Medicine

Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 514 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

E3 ubiquitin ligases: styles, structures and functions

Yang, Q., Zhao, J., Chen, D., & Wang, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00043-2 · Cited by 435 · see citing works

Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development

Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · see citing works

Translating p53 into the clinic

Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · see citing works

MDM2 inhibition: an important step forward in cancer therapy

Konopleva, M. Y., Martinelli, G., Daver, N. G., Papayannidis, C., Wei, A. H., Higgins, B., Ott, M., Mascarenhas, J. O., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376 · see citing works

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm

Soussi, T., & Wiman, K. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.001 · Cited by 366 · see citing works

Targeting the MDM2-p53 Interaction for Cancer Therapy

Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 364 · see citing works

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328 · see citing works

Peptide-mediated interactions in biological systems: new discoveries and applications

Petsalaki, E., & Russell, R. B. (2008) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2008.06.004 · Cited by 287 · see citing works

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · see citing works

A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidizationPreprint

Aylon, Y., Michael, D., Shmueli, A., Yabuta, N., Nojima, H., & Oren, M. (2006) · Genes & Development · doi:10.1101/gad.1447006 · Cited by 284 · see citing works

Molecular principles of cancer invasion and metastasis (Review)

Efferth (2009) · International Journal of Oncology · doi:10.3892/ijo_00000214 · Cited by 279 · see citing works

Functional proteomic profiling of AML predicts response and survival

Kornblau, S. M., Tibes, R., Qiu, Y. H., Chen, W., Kantarjian, H. M., Andreeff, M., Coombes, K. R., & Mills, G. B. (2008) · Blood · doi:10.1182/blood-2007-10-119438 · Cited by 265 · see citing works

A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.

Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261 · see citing works

Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future

Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 257 · see citing works

Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing

Robert, F., Barbeau, M., Ethier, S. D., Dostie, J., & Pelletier, J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0215-6 · Cited by 253 · see citing works

Glioblastoma Therapy: Past, Present and Future

Obrador, E., Moreno-Murciano, P., Oriol‐Caballo, M., López‐Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Bonet, L. G. G., Martínez‐Cadenas, C., Estrela, J. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 263 · see citing works

CDK8 Is a Stimulus-Specific Positive Coregulator of p53 Target Genes

Donner, A. J., Szostek, S. A., Hoover, J. M., & Espinosa, J. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.026 · Cited by 253 · see citing works

Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma

Singer, S., Socci, N. D., Ambrosini, G., Sambol, E. B., DeCarolis, P. L., Wu, Y. V., O’Connor, R., Maki, R. G., Viale, A. J., Sander, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0584 · Cited by 249 · see citing works

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245 · see citing works

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246 · see citing works

Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms

Allen, M. A., Andrysík, Z., Dengler, V. L., Mellert, H. S., Guarnieri, A. L., Freeman, J. A., Sullivan, K. D., Galbraith, M. D., Luo, X., Kraus, W. L., et al. (2014) · eLife · doi:10.7554/elife.02200 · Cited by 238 · see citing works

An Antagonist of Dishevelled Protein-Protein Interaction Suppresses β-Catenin–Dependent Tumor Cell Growth

Fujii, N., You, L., Xu, Z., Uematsu, K., Shan, J., He, B., Mikami, I., Edmondson, L. R., Neale, G. A. M., Zheng, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2726 · Cited by 232 · see citing works

An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells

Smalley, K. S. M., Contractor, R., Haass, N. K., Kulp, A. N., Atilla‐Gokcumen, G. E., Williams, D. S., Bregman, H. S., Flaherty, K. T., Soengas, M. S., Meggers, E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1538 · Cited by 229 · see citing works

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230 · see citing works

Nutlin-3a Activates p53 to Both Down-regulate Inhibitor of Growth 2 and Up-regulate mir-34a, mir-34b, and mir-34c Expression, and Induce Senescence

Kumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., Nagashima, M., Takenoshita, S., Yokota, J., & Harris, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2780 · Cited by 223 · see citing works

Efficient p53 Activation and Apoptosis by Simultaneous Disruption of Binding to MDM2 and MDMX

Hu, B., Gilkes, D. M., & Chen, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1140 · Cited by 214 · see citing works

Posttranslational Protein Modifications

Krueger, K. E., & Srivastava, S. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r600009-mcp200 · Cited by 215 · see citing works

Liposarcoma: Molecular Genetics and Therapeutics

Conyers, R. K., Young, S., & Thomas, D. M. (2010) · Sarcoma · doi:10.1155/2011/483154 · Cited by 213 · see citing works

HMGA2 is the partner of MDM2 in well‐differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon

Italiano, A., Bianchini, L., Keslair, F., Bonnafous, S., Cardot‐Leccia, N., Coindre, J., Dumollard, J., Hofman, P. M., Leroux, A., Mainguene, C., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23380 · Cited by 208 · see citing works

Computer-aided drug design: the next 20 years

Drie, J. H. V. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9142-y · Cited by 209 · see citing works

Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover

Fitzwalter, B. E., Towers, C. G., Sullivan, K. D., Andrysík, Z., Hoh, M., Ludwig, M. P., O’Prey, J., Ryan, K. M., Espinosa, J. M., Morgan, M. J., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.02.014 · Cited by 208 · see citing works

Identification and Characterization of the First Small Molecule Inhibitor of MDMX

Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198 · see citing works

The RING finger protein family in health and disease

Cai, C., Tang, Y., Zhai, J., & Zheng, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01152-2 · Cited by 194 · see citing works

Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy

Ke, B., Tian, M., Li, J., Liu, B., & He, G. (2016) · Medicinal Research Reviews · doi:10.1002/med.21398 · Cited by 188 · see citing works

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Sampson, C., Wang, Q., Otkur, W., Zhao, H., Lu, Y., Liu, X., & Piao, H. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1204 · Cited by 186 · see citing works

Tumor Suppressive MicroRNAs miR-34a/c Control Cancer Cell Expression of ULBP2, a Stress-Induced Ligand of the Natural Killer Cell Receptor NKG2D

Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 187 · see citing works

Targeting protein–protein interactions: Lessons from p53/MDM2

Murray, J. K., & Gellman, S. H. (2007) · Biopolymers · doi:10.1002/bip.20741 · Cited by 186 · see citing works

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function

Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182 · see citing works

Patterns of Early p21 Dynamics Determine Proliferation-Senescence Cell Fate after Chemotherapy

Hsu, C.-H., Altschuler, S. J., & Wu, L. F. (2019) · Cell · doi:10.1016/j.cell.2019.05.041 · Cited by 181 · see citing works

The BRET technology and its application to screening assays

Bacart, J., Corbel, C., Jockers, R., Bach, S., & Couturier, C. (2008) · Biotechnology Journal · doi:10.1002/biot.200700222 · Cited by 178 · see citing works

Targeting Apoptosis Pathways for New Cancer Therapeutics

Bai, L., & Wang, S. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 177 · see citing works

Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer

Crijns, A. P. G., Fehrmann, R. S. N., de Jong, S., Gerbens, F., Meersma, G. J., Klip, H. G., Hollema, H., Hofstra, R. M. W., Meerman, G. J. T., de Vries, E. G. E., et al. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000024 · Cited by 175 · see citing works

Attractor Landscape Analysis Reveals Feedback Loops in the p53 Network That Control the Cellular Response to DNA Damage

Choi, M., Shi, J., Jung, S. H., Chen, X. X., & Cho, K. (2012) · Science Signaling · doi:10.1126/scisignal.2003363 · Cited by 170 · see citing works

PAC-1 Activates Procaspase-3 in Vitro through Relief of Zinc-Mediated Inhibition

Peterson, Q. P., Goode, D. R., West-Szymanski, D. C., Ramsey, K. N., Lee, J. J. Y., & Hergenrother, P. J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.03.003 · Cited by 171 · see citing works

MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

Enge, M., Bao, W., Hedström, E., Jackson, S. P., Moumen, A., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.019 · Cited by 171 · see citing works

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170 · see citing works

Hdmx modulates the outcome of p53 activation in human tumor cells

Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163 · see citing works

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163 · see citing works

Targeting the DNA Damage Response in Cancer

Ljungman, M. E. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 163 · see citing works

Modeling of protein–peptide interactions using the CABS-dock web server for binding site search and flexible docking

Błaszczyk, M., Kurciński, M., Kouza, M., Wieteska, Ł., Dębiński, A., Koliński, A., & Kmiecik, S. (2015) · Methods · doi:10.1016/j.ymeth.2015.07.004 · Cited by 155 · see citing works

Procaspase-3 Activation as an Anti-Cancer Strategy: Structure−Activity Relationship of Procaspase-Activating Compound 1 (PAC-1) and Its Cellular Co-Localization with Caspase-3

Peterson, Q. P., Hsu, D. C., Goode, D. R., Novotny, C. J., Totten, R. K., & Hergenrother, P. J. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900722z · Cited by 156 · see citing works

Stereodivergent Direct Catalytic Asymmetric Mannich‐Type Reactions of α‐Isothiocyanato Ester with Ketimines

Lu, G., Yoshino, T., Morimoto, H., Matsunaga, S., & Shibasaki, M. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201101034 · Cited by 155 · see citing works

Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activityPreprint

Andrysík, Z., Galbraith, M. D., Guarnieri, A. L., Zaccara, S., Sullivan, K. D., Pandey, A., MacBeth, M. L., Inga, A., & Espinosa, J. M. (2017) · Genome Research · doi:10.1101/gr.220533.117 · Cited by 154 · see citing works

Exploring the Structural Requirements for Inhibition of the Ubiquitin E3 Ligase Breast Cancer Associated Protein 2 (BCA2) as a Treatment for Breast Cancer

Brahemi, G., Kona, F. R., Fiasella, A., Buac, D., Soukupová, J., Brancale, A., Burger, A. M., & Westwell, A. D. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901757t · Cited by 153 · see citing works

p53 Attenuates Cancer Cell Migration and Invasion through Repression of SDF-1/CXCL12 Expression in Stromal Fibroblasts

Moskovits, N. B.-C., Kalinkovich, A., Bar, J., Lapidot, T., & Oren, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2323 · Cited by 152 · see citing works

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

Nag, S. A., Zhang, X., Srivenugopal, K. S., Wang, M.-H., Wang, W., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660325 · Cited by 151 · see citing works

Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists

Shen, H., & Maki, C. G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 143 · see citing works

Therapeutics targeting p53-MDM2 interaction to induce cancer cell death

Koo, N., Sharma, A. K., & Narayan, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095005 · Cited by 153 · see citing works

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways

Dey, A., Tergaonkar, V., & Lane, D. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2759 · Cited by 146 · see citing works

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 147 · see citing works

Design, Synthesis, and Evaluation of an α-Helix Mimetic Library Targeting Protein−Protein Interactions

Shaginian, A., Whitby, L. R., Hong, S., Hwang, I., Farooqi, B., Searcey, M., Chen, J., Vogt, P. K., & Boger, D. L. (2009) · Journal of the American Chemical Society · doi:10.1021/ja810025g · Cited by 144 · see citing works

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

Barbieri, E., Mehta, P. S., Chen, Z., Zhang, L., Slack, A., Berg, S. L., & Shohet, J. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0305 · Cited by 142 · see citing works

Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin

Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0200 · Cited by 140 · see citing works

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas

Sarek, G., Kurki, S., Enbäck, J., Iotzova, G., Haas, J., Laakkonen, P. M., Laiho, M., & Ojala, P. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30945 · Cited by 141 · see citing works

Stereodivergent Direct Catalytic Asymmetric Mannich‐Type Reactions of α‐Isothiocyanato Ester with Ketimines

Lü, G., Yoshino, T., Morimoto, H., Matsunaga, S., & Shibasaki, M. (2011) · Angewandte Chemie · doi:10.1002/ange.201101034 · Cited by 139 · see citing works

TP53 in bone and soft tissue sarcomas

Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 137 · see citing works

Inhibition of p53 inhibitors: progress, challenges and perspectives

Sanz, G., Singh, M., Peuget, S., & Selivanova, G. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz075 · Cited by 137 · see citing works

Reactivation of p53: from peptides to small molecules

Brown, C. J., Cheok, C. F., Verma, C. S., & Lane, D. P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.004 · Cited by 135 · see citing works

Repurposing CRISPR/Cas9 for in situ functional assaysPreprint

Malina, A., Mills, J. R., Cencic, R., Yan, Y., Fraser, J., Nederveen-Schippers, L. M., Paquet, M., Dostie, J., & Pelletier, J. (2013) · Genes & Development · doi:10.1101/gad.227132.113 · Cited by 132 · see citing works

Hsp27 Modulates p53 Signaling and Suppresses Cellular Senescence

O’Callaghan-Sunol, C., Gabai, V. L., & Sherman, M. Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2441 · Cited by 134 · see citing works

p53 Attenuates Lipopolysaccharide-Induced NF-κB Activation and Acute Lung Injury

Liu, G., Park, Y.-J., Tsuruta, Y., Lorne, E., & Abraham, E. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803526 · Cited by 129 · see citing works

Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme

Villalonga-Planells, R., Coll-Mulet, L., Martínez‐Soler, F., Castaño, E., Acebes, J.-J., Gimenez‐Bonafé, P., Gil, J., & Tortosa, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018588 · Cited by 128 · see citing works

Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53

Kostic, M., Matt, T., Martinez-Yamout, M. A., Dyson, H. J., & Wright, P. E. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.08.027 · Cited by 128 · see citing works

Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells

Maimets, T., Neganova, I. E., Armstrong, L., & Lako, M. (2008) · Oncogene · doi:10.1038/onc.2008.166 · Cited by 127 · see citing works

Deubiquitinating Enzymes as Novel Anticancer Targets

Nicholson, B., Marblestone, J. G., Butt, T. R., & Mattern, M. R. (2007) · Future Oncology · doi:10.2217/14796694.3.2.191 · Cited by 127 · see citing works

Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer

Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125 · see citing works

Towards genome-scale signalling-network reconstructions

Hyduke, D. R., & Palsson, B. Ø. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2750 · Cited by 125 · see citing works

Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

Secchiero, P., Corallini, F., Gonelli, A., Dell’Eva, R., Vitale, M., Capitani, S., Albini, A., & Zauli, G. (2006) · Circulation Research · doi:10.1161/01.res.0000253975.76198.ff · Cited by 125 · see citing works

Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy

Vassilev, L. T. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-sy18-01

Abstract 977: Elevated MDM2 protein contributes to activity of MDM2 antagonists by enabling p53 induction of antitumor microRNAs

Xia, M., Huang, B., Chu, W., & Vassilev, L. T. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-977

Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics

Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271 · see citing works

Elevated MDM2 contributes to antitumor activity of p53-MDM2 binding inhibitors

Xia, M., Knezevic, D., Tovar, C., Heimbrook, D. C., & Vassilev, L. T. (2007) · Molecular Cancer Therapeutics

Abstract C128: Small-molecule antagonists of MDM2 and MDMX.

Thompson, T., Graves, B. J., Xia, M., Janson, C. A., Lukacs, C., Deo, D. D., Huang, K., Tovar, C., Lovey, A. J., Wanner, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c128